2상모집 중

A Study of Elritercept Alone or Together With Ruxolitinib in Adults With Myelofibrosis

연구 개요

The main aim of this study is to learn how safe elritercept is and how well it is tolerated when taken alone and in combination with the JAK inhibitor, ruxolitinib. Other aims are to learn about the effects of elritercept on the signs and symptoms of MF when taken with or without ruxolitinib and to learn how elritercept affects the body, how the body processes elritercept, and the effects of elritercept on anemia when taken with or without ruxolitinib The study will also check on how safe elritercept is and how well it is tolerated.

스폰서
리드: 다케다
적응증
Myelofibrosis
중재
Elritercept, Ruxolitinib
목표 등록
135
시작일
2021-12-16
완료(예정)
2030-02-28

BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.